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Abstract
Activities of microsomal monooxygenases (MO) and
epoxide hydrolase (EH) and cytoplasmic glutathione-
S-transferases (GST) will contribute to controlling
the pool of reactive intermediates, enzymatically
derived from polynuclear aromatic hydrocarbons
(PAH) within the cells of target organs such as the
human long. Therefore, we studied what interin-
dividual differences exist in these enzyme activities
and whether there is a correlation between the ac-
tivities of these epoxide forming and metabolizing
enzymes in preparations from peripheral lung
samples and the occurrence of bronchogenic car-
cinomas in smokers and non-smokers. 57 samples
obtained from surgery were studied. Among them
were 12 samples from non-smoking patients without
cancer as a control group. It is not known whether
this control group behaves, with respect to the in-
vestigated parameters, identically to fully healthy
people, since in all cases indications existed which
justified the removal of lung biopsies. Using very
sensitive standard assays with benzo[a]pyrene,
biphenyl, 7-ethoxyresorufin and 7-ethoxycoumarin
as substrates, MO activity could only be determined
as O-deethylatlon of 7-ethoxycoumarin and only
after modification of the assay method. Evidence
was obtained for the presence of a diffusible, but not
dialyslble, MO inhibitor in human lung microsomes.
The MO activity (substrate: 7-ethoxycoumarin) in
this fraction was extremely low in human (100-fold
lower than in rat lung preparations), whereas EM
(substrate: benzo[a]pyrene 4,5-oxide) was slightly
(about 2-fold) higher in human and GST (substrate:
2,4-dinitrochlorobenzene) had similar activities in
both species. Interindividual variations of enzyme ac-
tivities in human lung were considerable: MO,
40-fold: EH, 5-fold; GST 10-fold. Compared to the
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control group (non-smokers without cancer) MO ac-
tivities were slightly but significantly higher in lungs
from bronchogenic carcinoma patients whether they
were smokers (170% of controls, p < 0.0005) or non-
smokers (320% of controls p < 0.025). MO activities
of smokers without cancer were only very slightly
elevated (140%) of controls, p < 0.05). Specific EH
activities compared to the control group were slightly
but significantly increased in smokers without cancer
(160% of controls, p < 0.0125) and in bronchogenic
carcinoma patients whether they used tobacco pro-
ducts (13076 of controls, p < 0.005) or not (140% of
controls, p < 0.05). Specific GST activities showed
no significant differences (p > 0.1) between the
various groups studied. The substrate specificity of
human lung EM, which was studied using five
K-region epoxides of various PAH as substrates, cor-
responded to that in human and rat liver and In
human, mouse and rat skin and to the pure enzyme
isolated from rat liver. In contrast to ret liver
hepatoma preparations, where EHI had been shown
to be increased in the tumor tissue and had been iden-
tified as a preneoplastic antigen, EH activity in lung
microsomal preparations from samples of peripheral
squamous cell carcinomas of two subjects had in the
tumor tissue only one third of the activity of non-
diseased areas of the same lung.
Introduction
Polynuclear aromatic hydrocarbons (PAH)* are
widespread airborne pollutants. They are consti-
tuents of cigarette smoke, the inhalation of which is
associated with an increased risk of bronchogenic
carcinoma (1), one of the most frequent cancers in
man.
However, PAH exert their adverse effects only
after metabolic activation (2-10). Subcellular frac-
tions of mammalian organs catalyse the metabolism
of a great number of endogenous and exogenous
compounds (11-13), and are responsible for the for-
mation of electrophilically reactive intermediates of
PAH leading to their covalent binding to tissues con-
stituents including proteins and nucleic acids and to
cytotoxic, mutagenic and carcinogenic effects (2-10).
PAH are transformed by MO to electrophilically
reactive epoxides (monofunctional arene oxides)
which may bind to tissue constituents (14) but are fre-
quently so rapidly inactivated by EH and/or GSH
(15,16) that their contribution to toxic effects is
minor in many situations. In angular PAH those pro-
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ducts of the EH-catalyzed reaction which have their
hydroxyl groups at the two positions of the benzoring
opposite to the bay region can be transformed by a
second MO-cataJyzed step to vicinal dihydrodiol-bay
region epoxides (17,18). Results from the past few
years suggest that these (e.g. benzo[a]pyrene
7,8-dihydrodiol 9,10-oxide) might be the most potent
mutagens and carcinogens formed from several
angular PAH, especially benzo[a]pyrene (19-24) one
of the most widely distributed and most intensively
studied PAH. Thus monooxygenases (MO), epoxide
hydrolase (EH) and glutathione-S-transferases (GST)
are critical for the control of reactive metabolites
derived from PAH.
Most of these studies were performed with liver
tissue from experimental animals. However, some
pertinent information on human lung is also
available: PAH are metabolized by human lung sub-
cellular fractions and cultured bronchial cells to
epoxides, dihydrodiols and diol epoxides (25-29).
Harris et al., determined the specific activity of ben-
zo[a]pyrene MO and benzo[a]pyrene 4,5-epoxide
hydrolase in human bronchial mucosa explants (30)
and Cantrell etal., measured benzo[a]pyrene hydrox-
ylase in human pulmonary macrophages (31,32).
McLemore et al. (32), reported on a connection bet-
ween the occurrence of lung tumors and the level of
aryl hydrocarbon hydroxylase AHH (reflecting those
MO forms which transform benzo[a]pyrene to
fluorescent phenols) in alveolar macrophages.
Referring to the studies of Kellermann et al. (33),
they suggested a correlation between the AHH activi-
ty in pulmonary macrophages and AHH induction in
lymphocytes in the same subject for non-smoking
cancer patients (32). However, extensive studies by
other investigators have failed to confirm a connec-
tion between AHH inducibility in lymphocytes and
the risk of bronchogenic carcinoma development
while some studies could reproduce these results to
various extent (34-39). One of the reasons for these
confusing and contradictory results may be the fact
that the attempted correlation was restricted to AHH
whereas other MO forms and further enzymes such
as EH and GST also contribute to the control of reac-
tive metabolites of PAH.
Therefore in this study, three specific enzyme ac-
tivities which play an important role in controlling
the pool of electrophilically reactive PAH in-
termediates were measured simultaneously in 57
human lung samples. MO and GST were determined
by broad-spectrum substrates which are converted by
many of their multiple forms. Benzo[a]pyrene
4,5-oxide was used as a substrate for EH, where the
situation with respect to possible broad-spectrum
substrates for multiple forms is as yet not resolved.
MO is localized predominantly in the microsomal
fraction whilst several other membrane fractions
possess much lower and the cytoplasmic fraction no
measurable activity (13). GST activity is very high in
the cytoplasmic fraction (40), whilst membrane frac-
tions possess much lower albeit significant activities
(41-43). These enzymes were investigated in the pre-
sent study in those subcellular fractions where they
are predominantly located, MO in the microsomal
and GST in the cytoplasmic fraction. EH is localized
both in membrane (4) and cytoplasmic (44) fractions.
The activity of the cytoplasmic EH is quite high for
some substrates (44) but very low for all epoxides
derived from PAH tested to date (45), whereas the
microsomal EH is very active towards the latter (16).
Amongst the various membrane fractions the
microsomal had by far the highest activity (13). EH
activities were therefore investigated in microsomal
fractions in this study. Some of these individual lung
samples had already been measured earlier and the
results have been communicated in preliminary form
in a meetings proceedings (46). Since the population
in that preliminary study was so small, which was
especially true for the control group, medical indica-
tion for thoracotomy in non-cancer patients being in-
frequent (n = 7, but now 12), none of the differences
were statistically significant. The present study shows
significant differences between the control and each
of the three other groups in MO and EH but not GST
activities. Moreover in the preliminary meeting
report (46) patients with primary cancers outside the
lung having lung metastasis were included (this group
was called "lung-cancer patients"), whilst the greater
number of samples from patients with primary bron-
chogenic carcinoma now available has allowed the
formation of an exclusive group now called "bron-
chogenic carcinoma".
Materials and Methods
Chemicals
[3H]Benzo[a]pyrene (generally labelled, specific ac-
tivity 21 Ci/mmol) was purchased from the Radio-
chemical Centre, Amersham, UK and diluted to a
specific activity of 1.25 mCi/mmol.
[3H]Benzo[a]pyrene 4,5-oxide was synthesized accor-
ding to the method of Dansette and Jerina (47) under
conditions as described (48) and had a specific activi-
ty of 1.2 mCi/mmol. The other tritium-labelled
epoxides were a generous gift from Dr P.Sims, In-
stitute of Cancer Research, Royal Cancer Hospital,
London, UK. They were generally labelled. The
specific radioactivities used were (mCi/mmol): phen-
anthrene 9,10-oxide, 3.8; 7-methylbenz[a]anthracene
5,6-oxide, 10.0; benz[a]anthracene 5,6-oxide,
2.2;3-methylcholanthrene 11,12-oxide, 3.0.
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7-Ethoxycoumarin was prepared by standard pro-
cedure as described (49). Ethoxyresorufin was a
generous gift from Dr J.Dent, DIIT, Research
Triangle Park, NC, USA.
Other chemicals were of the purest grade commer-
cially available.
Animals
Adult male Sprague-Dawley rats (200-220 g) were ob-
tained from Versuchstierzuchtanstalt WIGA,
Sulzfeld, GFR.
Patient population and statistical analysis
Lung samples from 57 patients suffering from bron-
chogenic carcinoma or non-tumorous diseases were
obtained from surgery, frozen immediately in liquid
nitrogen and kept at -70°C until preparation. No
measurable loss in enzyme activities was observed
after a storage under these conditions for at least one
year. Except where specified all samples were from
non-tumorous peripheral tissue. None of the patients
investigated was on long-term treatment with drugs
known to be inducers of the microsomal enzyme
system in man. In addition, none of the subjects had
received x-ray treatment or chemotherapy prior to
surgery.
Diagnoses were confirmed histologically. Only
those patients were classified as non-smokers who
had not used tobacco products for at least 6 months.
Observations by Cantrell et al. had shown that induc-
ed monooxygenase (substrate: benzo[a]pyrene) ac-
tivity levels in pulmonary macrophages of smokers
revert to levels of non-smokers within 3 months after
cessation of smoking (31). Most of the non-smokers
had not smoked for a much longer time (means of 11
years for cancer patients and 26 years for non-cancer
patients). All smokers smoked at least until the third
last day before the biopsy was taken. A survey of the
subjects is shown in Table I.
For statistical analysis of the specific enzyme ac-
tivities of the different groups of patients a mean and
its standard deviation were calculated. The variances
of all groups were tested by an F-test for homo-
geneous distribution (50). If the variances of two
samples were found to be significantly different, a
Wilcoxon-Rank test was performed, while in the case
of a homogeneous distribution a Student T-test for
unconnected random samples was performed (50).
Differences with p < 0.05 were considered as
statistically significant.
Preparation of subcellular fractions
Rats were killed by cervical dislocation. The lungs
from groups of three animals were excised and pool-
Table I
Details of patients included in this study
Total
Cigarette smokersb
Nonsmokersb>c
Male
Female
Age
Mean age
Noncancer
19
7
12
14
5
8-73
53
Bronchogenic car-
cinoma*
38
31
7
34
4
39-80
58
a) Patients with primary tumors outside the lung having lung
metastasis were not included.
b) The distribution of sex and age was similar for smokers and
non-smokers.
c) Patients who had never smoked or who had not smoked for at
leajt 6 months prior to surgery.
ed in ice-cold 1.15% KC1 containing 10 mM
K-phosphate buffer, pH 7.4. The organs were freed
from adhering tissues. The frozen samples from
human lung (see above) were rapidly warmed up to
0°C and transferred into the same medium. Tissues
were minced and homogenized in about 3 volumes of
1.15% KC1 containing 10 mM K-phosphate buffer
pH 7.4 in an Ultra Turrax homogenizer. The homo-
genates were centrifuged at 10,000 g for 15 min and
the resulting supernatant fractions were centrifuged
at 100,000 g for 1 h. The 100,000 g supernatant frac-
tion was isolated while the microsomal pellet was
washed by resuspending in buffered KC1 and recen-
trifuging at 100,000 g for 30 min. Washed
microsomes were resuspended again in the same
medium, which resulted in final concentrations of 1-8
mg protein/ml for material from both rat and human
lung. Protein recovery was low in human lung
microsomes (1.61 ± 0.42 mg/g wet tissue weight)
compared to rat lung microsomes (4.22 ± 0.41 mg/g
wet tissue weight). Protein concentrations were deter-
mined by the method of Lowry et al. (51).
Activities of the three enzymes measured were
found to be differently stable in ice cold suspensions
of subcellular fractions. Whereas ethoxycoumarin-
O-deethylase showed a measurable loss in activity
after only 4 h, benzo[a]pyrene 4,5-oxide hydrolase
remained stable for at least 24 h, and GST had cons-
tant activities during 3 days. Therefore assays were
performed promptly after preparation in the se-
quence MO, EH, GST.
Assays
MO activities were determined with 4 different sub-
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strates. The assay of 7-ethoxycoumarin O-dealkyl-
ation was carried out according to the method of
Ullrich and Weber (52) with one modification.
Cofactor concentrations in the assay mixture were
altered, because both NADP and umbelliferone
fluoresce at 460 nm when excited at 385 nm. We
reduced the NADPH amount within the range of
saturating concentrations in order to diminish the
resulting fluorescence quenching, which was impor-
tant when tissues with extremely low enzyme ac-
tivities such as the human lung were studied. The op-
timal conditions adopted for this study were: 4 x
10~5 M NADPH, 2 x lO"5 M NADH, 3 x 10~3 M
glucose 6-phosphate, 0.56 U glucose 6-phosphate
dehydrogenase in the assay mixture. Benzo[a]pyrene
hydroxylase was determined by the methods of
Nebert and Gelboin (53) and DePierre et al. (54).
Biphenyl hydroxylase (2-hydroxylation and
4-hydroxylation) was measured according to a
method of Creaven et al. (55). Ethoxyresorufin
deethylation was measured as described by Burke
and Mayer (56). EH activities were determined using
the radiometric extraction assay with
pH]benzo[a]pyrene 4,5-oxide as substrate (48) and
for the other substrates as described (16). GST ac-
tivities were measured as described by Habig et al.
(57), using 2,4-dinitrochlorobenzene as substrate.
All results reported were obtained under condi-
tions where linearity with time and protein was ascer-
tained. All samples were assayed in duplicates. Two
samples were divided each into two and these
prepared and measured separately. Intra- and inter-
experimental variation proved to be low ( < 5<7o).
Results and Discussion
Human lung microsomes have a very low MO activi-
ty compared to rat lung fractions. This was not due
to freezing or storing of the tissue. Four human lung
samples from smoking cancer patients and one from
a non-smoking patient without cancer had similar
specific MO activities when they were measured im-
mediately after surgery or after storage at -70°C.
The same was true for EH and GST. In order to find
optimal assay conditions for human lung MO activi-
ty, several substrates and assay methods were tested
using the most sensitive assays. O-Deethylation of
ethoxycoumarin was the only assay which gave
measurable activities after the modification described
in Materials and Methods. Specific activities in rat
lung microsomal fractions were determined in
parallel as a positive control (Table II). The use of
7-ethoxycoumarin has the advantage that, on one
hand it is a broad-spectrum substrate converted by
several MO forms which are inducible by different
groups of chemicals (58). On the other hand, there
Table II
Substrate specificities of rat and human lung monooxygenases
Substrates
Benzo[a]pyrene hydroxylase0
Benzo[a]pyrene hydroxylase"1
Ethoxycoumarin O-deethylase
EthoxyTesorufin O-deethylase
Biphenyl 2-hydroxylase
Biphenyl 4-hydroxylase
Specific activity
(pmol product per mg
per min)
Rat lung* Human lungb
4.2 ± 0.3 n.d.
2.1 ± 0.2 n.d
68.4 ± 2.9 1.2
detectable0 n.d.
42 ± 6 n.d.
65 ± 5 n.d.
Assays were carried out with microsomal fractions from rat and
human lung. Microsomes from human lung were samples of
smokers with bronchogenic carcinomas which were prepared im-
mediately after surgery.
a) Values represent means ± S.D. The organs of three animals
were pooled. Assays were performed using three aliquots of the
microsomal pool each of which was measured in duplicate at two
protein concentrations.
b) Results of determination in three human lungs. Determinations
were performed in samples of individual lungs, each of which was
measured in duplicate at two protein concentrations, n.d. = not
detectable.
c) Assay method after Nebert and Gelboin (53).
d) Assay method after DePierre et al. (54).
e) Specific enzyme activity cannot be given quantitatively for lack
of a product standard.
exist data which indicate that this substrate is
especially well transformed by that group of
cytochrome P-450's (P-448, Pi-450) which is also
especially active in the biotransformation of PAH.
These data include concerted inductions and com-
mon genetic control of inducibility (59).
One of the reasons for the extremely low specific
enzyme activity in human lung preparations could be
inhibitors present in the tissue. We therefore in-
cubated rat lung and human lung microsomes
together. It could be demonstrated that 7-ethoxy-
coumarin O-deethylase activity of the rat lung
microsomes was inhibited by the presence of human
lung microsomes (Table III). This finding suggested
that diffusible inhibitors may be present in human
lung microsomal fractions. Although higher propor-
tions of human to rat lung microsomes generally led
to higher inhibition (Table III), this dependence was
not linear, possibly due to limited accuracy of the
assay where the remaining activity was only slightly
over blank, or else due to limited diffusibility of the
inhibiting factor. Indeed, dialysis with 10 mM EDTA
could not remove this inhibitor. The somewhat
higher MO activities with the use of EDTA and
830
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Table III
Inhibition of rat lung 7-ethoxycoumarin O-deethylase by human
lung microsomes*
Theoretical
Ratio Specific activity specific activity % Inhibition
rat/humanb in rat lung in rat lung of rat lung
microsomesc microsomesd monooxygenasee
10/0
9/1
3/1
1/1
1/3
1/9
63.0
31.8
20.0
15.8
3.0
0 «0 .1)
63.0
56.7
47.3
31.5
25.8
6.3
0
44
58
50
81
total inhibition
a) The microsomal fractions of rat lung and human lung (from a
smoking cancer patient), both with equal protein concentrations,
were mixed in different ratios, but with a constant total protein
concentration in the assay mixture (0.42 mg). The assay was car-
ried out after a preincubation time of 15 min at 37°C.
b) Ratio of rat to human lung microsomes (w/w).
c) Specific enzyme activities given as pmol product per mg protein
per min.
d) Supposed enzyme activities in rat lung microsomes, given as
pmol product per mg protein per min without human lung micro-
somes.
e) The inhibition was calculated assuming zero contribution of
human lung MO activity to the measured total MO activity.
Although in the sample containing the highest amount of human
preparation no MO activity was measurable, the assumption may
not be fully correct in the samples where the remaining activity was
very little above blank (samples having more human than rat lung
microsomes).
glycerol in microsomal suspension from human lung
reported by Prough et al. and Stpal et al. (26,28,29)
may be due to partial removal of inhibitor.
Specific MO activities in human lung microsomes
from the control group were about two orders of
magnitude lower than in rat lung preparations with
the only substrate which allowed quantitation,
7-ethoxycoumarin (Table II). This is, at least in part,
due to the presence of an MO inhibitor in these
human lung preparations (Table III). On the other
hand, specific EH activities in human microsomes of
the control group were slightly higher than in rat lung
microsomes (about 2-fold) and GST activities were
very similar to those of the rat (Table IV).
Considerable interindividual variations were
observed in enzyme activities of human lung samples.
Figure 1 shows a 40-fold variation from the lowest to
the highest extremes for MO, a 5-fold variation for
EH and a 10-fold variation for GST. This coincides
with findings of other investigators (26,28,29,60)
concerning specific activities of MO, glucuronyl- and
sulfotransferase in human lung preparations, with
results on the variation in metabolism of
benzo[a]pyrene by human lung tissue (61) and with a
report of Harris et al. (62) on a 75-fold inter-
individual variation for the binding of benzo[a]-
pyrene to DNA in cultured human bronchus ex-
plants. The wide range in specific enzyme activities
between individuals may in part reflect genetic dif-
ferences but is also influenced by, e.g., environmen-
tal factors or variation in the composition of cells
between the samples.
Significant differences in some of these enzyme ac-
tivities were observable between the different groups
of patients (Table IV). Compared to non-smoking
patients without cancer (control group), non-
smoking cancer patients had 3-fold higher specific
MO activities (p < 0.025) and 1.4-fold higher EH ac-
tivities (p < 0.05), whereas no significant differences
in specific GST activities were observable between
the two groups (p > 0.1). A similar relation existed
when the control group was compared to smoking
cancer patients. The latter group had 1.7-fold higher
specific MO activities (p < 0.0005), 1.3-fold higher
specific EH activities (p < 0.005), but again not
significantly different specific GST activities (p
> 0.1) in comparison with the control patients. Pa-
tients who were smokers, but not suffering from
bronchogenic carcinoma, had slightly but significant-
ly higher MO (1.4-fold, p < 0.05) and EH (1.6-fold,
p < 0.0125). Again, specific GST activities did not
differ between these two groups (p > 0.1).
On the other hand, no significant differences in
any of the three enzyme activities were noticed bet-
ween smokers without cancer and those with
bronchogenic carcinoma nor between cancer patients
who smoked and those who did not. Differences in
specific activities between non-smoking cancer pa-
tients and smokers without cancer were not
statistically significant for EH and GST (p > 0.1),
whilst the difference in MO just reached statistical
significance (p < 0.05).
Thus the connection between smoking or the
development of malignant tumors dependent on the
use of tobacco products and the level of specific ac-
tivities of enzymes which are important for the meta-
bolism of PAH in human lung appears to be com-
plex. Furthermore it should be emphasised that for
surgical reasons the lung tissues were from peripheral
parts of the organ which contained mostly alveolar
tissue and small bronchioles where only a minority of
human cancers originate, while the majority of lung
cancers develop from bronchial epithelium.
However, the following trends may be deduced.
The specific activity of GST was very similar in all
groups, whilst MO and EH were higher in all cancer
and smoker groups compared to controls. These dif-
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Table IV
Activities of epoxide-forming and -metabolizing enzymes in human lung subcellular fractions of various groups of samples and species dif-
ferences between human and rat lung.
Source of lung
preparations
Monooxygenaseb
Specific activities* (% of controls)
Epoxide hydrolase1 Glutathione
S-transferased
Patient groups
A Control0
(no cancer. Non-smokers)
B No cancerf
Smokers
C Bronchogenic*
carcinoma
Non-smokers
D Bronchogenic
carcinoma
Smokers
Rath
0.62 ± 0.26 (100)
0.88 ± 0.37 (142)
1.96 ± 1.40(316)
1.05 ± 0.20(169)
68.4 ± 2.9
739 ± 198 (100)
1,219 ± 428 (165)
1,048 ± 513 (142)
954 ± 233 (129)
384 ± 21
78,400 ± 47,000 (100)
68,000 ± 36,300 (87)
80,900 ± 44,500 (103)
64,000 ± 32,200 (82)
76,000 ± 3,200
a) Specific activities are given as pmol product per mg protein per min. Numbers in brackets represent ft of controls. Values are means ±
S.D. Samples were measured individually in duplicates at two protein concentrations.
b) Assays were carried out with microsomal fractions using 7-ethoxycoumarin as substrate.
c) Assays were carried out with microsomal fractions using benzo[a]pyrene 4,5-oxide as substrate.
d) Assays were carried out with 100,000 g supernatant fractions using 2,4-dinitrochlorobenzene as substrate.
p <0.05(MO), p <0.0125(EH), p >0.1 (GST),
p < 0.025 (Mf>^  o <0.05 (EH), D >0.1 (GST),
p < 0.005 (MO;, p< 0.05 (EH), p > 0.1 (GST).
p < 0.05 (MO), p > 0.1 (EH), p > 0.1 (GST),
p > 0.1 (MO), p > 0.05 (EH), p > 0.1 (GST).
p < 0.05 (MO), p > 0.1 (EH), p > 0.1 (GST),
h) Values represent means ± S.D. The organs of three animals were pooled. Assays were performed using three aliquots, each of which was
measured in duplicate at two protein concentrations.
e) Compared to group B:
Compared to group C:
Compared to group D:
0 Compared to group C:
Compared to group D:
g) Compared to group D:
ferences between the mean MO and EH activities of
the various groups compared with the controls were
rather modest (maximally 3.2-fold) but all statistical-
ly significant. Cantrell et al. (31) found a 12-fold
AHH induction in human alveolar macrophages
from healthy smokers compared to non-smokers.
Since in our study MO levels of smokers did not dif-
fer from controls as distinctly as in the above study,
it may appear that macrophages are among the cell
types of higher inducibility within the cell population
present in the samples we investigated.
The specific initial rates for the hydration of five
K-region epoxides by human lung microsomal EH
are shown in Figure 2. The rate of hydration of all
substrates was easily measurable and the order of
rates was phenanthrene 9,10-oxide > 7-methylbenz-
[a]anthracene 5,6-oxide ^benzo[a]pyrene 4,5-oxide
sbenz[a]anthracene 5,6-oxide > 3-methylcholan-
threne 11,12-oxide (Figure 2). The relationship bet-
ween the substrates is very similar to that found in
microsomal preparations from human and rat liver,
from human, rat and mouse skin and with pure EH
isolated from rat liver (16,63-65). This suggests the
presence of either one enzyme or different enzymes
under the same control in these species and tissues.
Specific EH activity was determined in two
samples of bronchogenic carcinoma tissue. Micro-
somes were prepared from two tumors histologically
specified as squamous cell bronchogenic carcinomas,
situated at peripheric areas of the lung. Enzyme ac-
tivities in a non-diseased, also peripherically situated
lung area of the same two subjects, were also deter-
mined. In both cases specific activity of microsomal
EH was three fold lower in the preparation from the
tumors (Table V). This is in marked contrast to the
situation in rat liver where, as Levin et al. (66) have
reported, a precarcinogenic antigen in preneoplastic
nodules, which have developed following administra-
tion of 2-acetylaminofluorene, was identified as
microsomal EH. They found a 5- to 7-fold higher EH
activity in hyperplastic nodules and in chemically in-
duced hepatomas compared to livers of control rats.
The results with the two squamous cell bronchogenic
carcinomas obtained in this study indicate that an in-
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Fig. 1. Interindividual differences of specific enzyme activities
(pmol product per mg protein per min) of microsomaJ MO,
microsomal EH and cytoplasmic GST in human lung samples. The
lowest (highest) specific enzyme activity measured was 0.10 (4.15)
pmol product per min per mg protein for MO (substrate: 7-ethoxy-
coumarin), 406 (1890) pmol product per min per mg protein for
EH (substrate: benzo[a]pyrene 4,5-oxide) and 15.4 (156) nmol pro-
duct per min per mg protein for GST (substrate: 2,4-dinitrochloro-
benzene).
Table V
Epoxide hydrolase activity in microsomes from tumor tissue and
non-diseased lung areas of two bronchogenic carcinoma patients.
Source
Patient
A)
B)
Patient
A)
B)
of lung sample
I
Tumor
Non-diseased tissue
II
Tumor
Non-diseased tissue
Specific activity*
(pmol product
per mg protein
per min)
460
1,440
380
1,106
Ratio
A/B
0.32
0.34
Samples of histologically verified squamous cell carcinomas and of
microscopically non-diseased areas of the lungs were taken out
during thoracotomy. All samples weTe taken from peripheric parts
of the lungs. Preparation of subcellular fractions and assays were
performed immediately after surgery.
a) Assays were carried out with microsomal fractions using
benzo[a]pyrene 4,5-oxide as substrate.
crease of EH in tumor tissue does not represent a
general phenomenon.
In this study conditions were established where
specific MO activities (as ethoxycoumarin
3000 -
2000
1000
Fig. 2. Substrate specificity of human lung microsomal EH
towards five K-region epoxides derived from PAH. The values
represent the average ± S.D. of three measurements of lung
microsomes from a smoking cancer patient. Microsomes were in-
cubated with the tritium-labelled epoxides for 20 min at 37°C.
Assays were carried out as described (16).
O-dealkylation) became clearly measurable in human
lung microsomal suspensions. These specific ac-
tivities were determined simultaneously with those of
EH and GST in lung samples of different groups of
patients.
After a long term use of tobacco products the pat-
tern of activities of the three enzymes differed from
that of the control patients. This change of the pat-
tern resembled that of the cancer patients, whether
they were smokers or not. Further investigations on
these enzymes in cell types and lung regions known to
be affected most often by cancer development will be
necessary to deepen our understanding of relations
between carcinogen metabolizing enzymes and bron-
chogenic carcinomas.
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